Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DocCheck AGHAM:AJ91 +0.85%71 Return-on-Tangible-Equity is 14.58% as of Dec. 2025, which is 6% above its 10-year median of 13.78. GuruFocus rates HAM:AJ91 with a GF Score™ of 71/100 and a GF Value™ of €9.52. The stock has 3 warning signs investors should review. Among 576 Healthcare Providers & Services companies, DocCheck AG ranks better than 57.64% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. DocCheck AG's annualized net income for the quarter that ended in Dec. 2025 was €5.75 Mil. DocCheck AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €39.46 Mil. Therefore, DocCheck AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 14.58%.
The historical rank and industry rank for DocCheck AG's Return-on-Tangible-Equity or its related term are showing as below:
HAM:AJ91'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.06 Med: 13.78 Max: 35.42
Current: 13.52
During the past 13 years, DocCheck AG's highest Return-on-Tangible-Equity was 35.42%. The lowest was 6.06%. And the median was 13.78%.
HAM:AJ91's Return-on-Tangible-Equity is ranked better than 57.64% of 576
companies
in the Healthcare Providers & Services industry
Industry Median: 10.17
vs HAM:AJ91: 13.52
DocCheck AG (HAM:AJ91) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
DocCheck AG Return-on-Tangible-Equity Related Terms
DocCheck AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for DocCheck AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:AJ91 vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, DocCheck AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocCheck AG Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocCheck AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where DocCheck AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.58% mean?
DocCheck AG (HAM:AJ91) has a Return-on-Tangible-Equity of 14.58% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on DocCheck AG and its competitors. This is near median its historical median of 13.78. Over the past decade, DocCheck AG's Return-on-Tangible-Equity has ranged from 6.06 to 35.42. According to the industry distribution chart, DocCheck AG ranks #244 out of 576 companies in the Healthcare Providers & Services industry, placing it in the top 42.4%.
Is DocCheck AG's Return-on-Tangible-Equity too high?
DocCheck AG's current Return-on-Tangible-Equity of 14.58% is near median its 10-year median of 13.78. Over the past 10 years, this metric has ranged from a low of 6.06 to a high of 35.42. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.17. DocCheck AG's value of 14.58% is 43.4% above this industry median. Based on the distribution chart, DocCheck AG ranks #244 out of 576 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, DocCheck AG has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does DocCheck AG's Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DocCheck AG ranks #244 out of 576 companies for Return-on-Tangible-Equity. This puts DocCheck AG in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.17. DocCheck AG's value of 14.58% is 43.4% above this benchmark. Historically, DocCheck AG's own Return-on-Tangible-Equity has ranged from 6.06 to 35.42 over the past decade. While the company's 10-year median is 13.78 vs. the industry median of 10.17, DocCheck AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.17, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocCheck AG's current Return-on-Tangible-Equity of 14.58% is 43.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on DocCheck AG and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocCheck AG's current Return-on-Tangible-Equity is 14.58%, which is near median its own 10-year median of 13.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocCheck AG stock overvalued right now?
DocCheck AG (HAM:AJ91) has a current Return-on-Tangible-Equity of 14.58%. The stock's GF Value™ is €9.52, compared to a current price of €11.90 — trading 25% above its estimated fair value. The current Return-on-Tangible-Equity is 14.58%, which is near median its 10-year median of 13.78 and 43.4% above the Healthcare Providers & Services industry median of 10.17. DocCheck AG's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For DocCheck AG (HAM:AJ91), the current Return-on-Tangible-Equity is 14.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocCheck AG (HAM:AJ91) Overvalued in 2026?
Based on GuruFocus' analysis, DocCheck AG stock appears to be overvalued.
The current stock price of €11.90 is trading 25% above its estimated GF Value™ of €9.52.
Key valuation signals for HAM:AJ91:
Return-on-Tangible-Equity: 14.58% (near median its 10-year median of 13.78)
GF Value™: €9.52 vs. price of €11.90 (25% above fair value)
Industry Position: 43.4% above the Healthcare Providers & Services median (#244 of 576)
No single metric tells the full story. See the HAM:AJ91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocCheck AG is a Germany-based company engaged in the healthcare sector. It operates through subsidiaries: antwerpes AG develops integrated communication concepts for the healthcare sector, including social media and digital communication with focus on e-marketing concepts, search engine optimization (SEO), search engine advertising (SEA) and search engine marketing (SEM); DocCheck Medical Services GmbH operates an online platform for healthcare professionals, such as physicians and pharmacists; DocCheck Medizinbedarf und Logistik GmbH wholesales medical products from third parties and also produces own medical products, and DocCheck Guano AG is a venture capital company with focus on e-health companies and promotes healthcare startups.
71GF Score
Get the complete analysis for HAM:AJ91
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:AJ91 has been successfully added to your 
